HIV and AIDS Articles
| |
FDA-approved
Treatments Experimental
Treatments
Top
New Articles
Guidelines |  |
Apricitabine (SPD754 / SPD756) • Apricitabine is an experimental nucleoside reverse transcriptase inhibitor (NRTI). • Apricitabine is being developed by Avexa, an Australian pharmaceutical company. The drug was first developed by BioChem Pharma (where it was called BCH10618). BioChem Pharma was then sold the Shire Pharmaceuticals (where the drug was called SPD754). Shire then sold the rights to develop the drug to Avexa. New NRTI Apricitabine Demonstrates Good Safety
in Early Clinical Trial - 8/22/08
|
| ||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||
